SPARCPharmaceuticals
Sun Pharma Advanced Research Company Ltd — Cash Flow Statement
₹114.89
-8.03%
Sun Pharma Advanced Research Company Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Depreciation | 12.27 Cr | 12.33 Cr | 11.56 Cr | 10.16 Cr | — |
| Free Cash Flow | -370.63 Cr | -455.70 Cr | -84.50 Cr | -240.91 Cr | — |
| Repayment Of Debt | -369.03 Cr | -17.46 Cr | -299.49 Cr | -262.55 Cr | — |
| Issuance Of Debt | 580.21 Cr | 64.41 Cr | 224.54 Cr | 107.00 Cr | — |
| Capital Expenditure | -10.34 Cr | -26.51 Cr | -15.39 Cr | -32.68 Cr | — |
| End Cash Position | 1.96 Cr | 5.33 Cr | 0.58 Cr | 1.22 Cr | — |
| Beginning Cash Position | 5.33 Cr | 0.58 Cr | 1.22 Cr | 9.30 Cr | — |
| Effect Of Exchange Rate Changes | 0.01 Cr | 20000.00 | 0.00 | -17000.00 | — |
| Changes In Cash | -3.38 Cr | 4.74 Cr | -0.64 Cr | -8.08 Cr | — |
| Financing Cash Flow | 199.26 Cr | 42.41 Cr | 616.76 Cr | 229.32 Cr | — |
| Interest Paid Cff | -8.42 Cr | -1.60 Cr | -8.21 Cr | -14.22 Cr | — |
| Net Issuance Payments Of Debt | 211.19 Cr | 46.95 Cr | -74.95 Cr | -155.55 Cr | — |
| Net Long Term Debt Issuance | 211.19 Cr | 46.95 Cr | -74.95 Cr | -155.55 Cr | — |
| Long Term Debt Payments | -369.03 Cr | -17.46 Cr | -299.49 Cr | -262.55 Cr | — |
| Long Term Debt Issuance | 580.21 Cr | 64.41 Cr | 224.54 Cr | 107.00 Cr | — |
| Investing Cash Flow | 157.66 Cr | 391.53 Cr | -548.28 Cr | -29.17 Cr | — |
| Interest Received Cfi | 14.55 Cr | 22.37 Cr | 1.87 Cr | 0.18 Cr | — |
| Net Investment Purchase And Sale | 152.86 Cr | 395.18 Cr | -535.23 Cr | -4.77 Cr | — |
| Sale Of Investment | 152.86 Cr | 420.18 Cr | 520.00 Cr | 50000.00 | — |
| Purchase Of Investment | 0.00 | -25.00 Cr | -1.06K Cr | -4.78 Cr | — |
| Net PPE Purchase And Sale | -9.74 Cr | -26.02 Cr | -14.92 Cr | -24.58 Cr | — |
| Sale Of PPE | 0.59 Cr | 0.49 Cr | 0.47 Cr | 8.10 Cr | — |
| Purchase Of PPE | -10.34 Cr | -26.51 Cr | -15.39 Cr | -32.68 Cr | — |
| Operating Cash Flow | -360.29 Cr | -429.19 Cr | -69.12 Cr | -208.23 Cr | — |
| Taxes Refund Paid | 8.83 Cr | -4.11 Cr | 5.37 Cr | 4.54 Cr | — |
| Change In Working Capital | -46.86 Cr | -27.33 Cr | 141.11 Cr | -26.05 Cr | — |
| Change In Other Current Liabilities | -16.93 Cr | 22.65 Cr | 56.48 Cr | 29.09 Cr | — |
| Change In Other Current Assets | 3.35 Cr | -63.09 Cr | 10.41 Cr | -26.38 Cr | — |
| Change In Payable | -29.29 Cr | -5.89 Cr | 76.67 Cr | -19.36 Cr | — |
| Change In Receivables | -0.43 Cr | 15.21 Cr | -5.01 Cr | -10.15 Cr | — |
| Other Non Cash Items | 8.36 Cr | -23.77 Cr | 0.05 Cr | 11.93 Cr | — |
| Provisionand Write Offof Assets | 0.00 | 2.05 Cr | 0.00 | — | -0.20 Cr |
| Depreciation And Amortization | 12.39 Cr | 12.51 Cr | 11.77 Cr | 10.16 Cr | — |
| Amortization Cash Flow | 0.13 Cr | 0.18 Cr | 0.21 Cr | — | — |
| Gain Loss On Investment Securities | -1.06 Cr | -3.18 Cr | -3.27 Cr | -0.46 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 0.85 Cr | 2.06 Cr | -1.68 Cr | -0.07 Cr | — |
| Gain Loss On Sale Of PPE | -0.03 Cr | -0.58 Cr | 0.11 Cr | -4.89 Cr | — |
| Net Income From Continuing Operations | -342.78 Cr | -386.83 Cr | -222.58 Cr | -203.40 Cr | — |
| Issuance Of Capital Stock | — | 0.00 | 702.78 Cr | 409.26 Cr | 0.00 |
| Net Common Stock Issuance | — | 0.00 | 702.78 Cr | 409.26 Cr | 0.00 |
| Common Stock Issuance | — | 0.00 | 702.78 Cr | 409.26 Cr | 0.00 |
| Net Short Term Debt Issuance | — | 46.95 Cr | -74.95 Cr | -155.55 Cr | — |
| Short Term Debt Payments | — | -17.46 Cr | -299.49 Cr | -262.55 Cr | — |
| Short Term Debt Issuance | — | 64.41 Cr | 224.54 Cr | 107.00 Cr | — |
| Net Other Investing Changes | — | 1000.00 | -1000.00 | — | — |
| Other Cash Adjustment Outside Changein Cash | — | — | — | -0.01 Cr | — |
| Net Other Financing Charges | — | — | — | -3000.00 | 0.01 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sun Pharma Advanced Research Company Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.